What's Happening?
KORU Medical Systems has announced its financial results for the first quarter of 2026, reporting a 22.1% increase in net revenues to $11.8 million compared to the same period in 2025. The growth was driven by higher consumable volumes and market share
gains in both domestic and international markets. Domestic core revenues increased by 11.7%, while international core revenues rose by 35.2%, supported by distributor purchases for pre-filled syringe conversions in key EU markets. The company's gross profit grew by 20% to $7.2 million, with a gross margin of 61.5%. KORU Medical also reported a net loss improvement of 31% to $0.8 million.
Why It's Important?
The strong revenue growth and improved financial performance highlight KORU Medical's successful market strategy and its ability to capitalize on the growing demand for subcutaneous infusion solutions. The company's expansion into international markets and its focus on new drug categories, including oncology, position it well for future growth. KORU Medical's strategic initiatives, such as advancing non-Ig pharma collaborations to Phase III clinical trials, demonstrate its commitment to innovation and market expansion. The company's ability to maintain a strong cash position and improve its net loss further underscores its financial resilience.
What's Next?
KORU Medical is well-positioned for continued growth, with plans to expand its market presence and product offerings. The company has reiterated its full-year 2026 guidance, expecting net revenues between $47.5 million and $50.0 million, representing growth of 15% to 22%. KORU Medical is also focused on achieving positive adjusted EBITDA and cash flow for the year. The company's strategic roadmap includes expanding its platform to access new therapies and geographies, supported by a scalable commercial model. KORU Medical's ongoing investments in research and development are expected to drive future growth and innovation.
